Lion Point Capital »

Innoviva shares owned by Lion Point Capital

Quarter-by-quarter ownership of Innoviva (INVA) shares owned by Lion Point Capital from 13F filings

Historical chart of Lion Point Capital investment in Innoviva

Tip: Access up to 7 years of quarterly data

All positions including Innoviva held by Lion Point Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Innoviva by Lion Point Capital

Quarter filed Position value Share count Share price at filing
2025-12-31 $164k 8.2k 19.99

More positions owned by Lion Point Capital

Milestone Pharmaceuticals (MIST)
Praxis Precision Medicines I Com New (PRAX)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Fennec Pharmaceuticals (FENC)
Jasper Therapeutics Com New (JSPR)
Benitec Biopharma Com New (BNTC)
Royalty Pharma Shs Class A (RPRX)
Geron Corporation (GERN)
Syndax Pharmaceuticals (SNDX)
Ardelyx (ARDX)
Cue Biopharma (CUE)
Disc Medicine (IRON)
Sarepta Therapeutics (SRPT)
Biohaven (BHVN)
Humacyte (HUMA)

View all positions for Lion Point Capital

Top funds holding Innoviva

BlackRock
Vanguard Group
Dimensional Fund Advisors
Renaissance Technologies
Sarissa Capital Management
State Street Corporation
Arrowstreet Capital, Limited Partnership
American Century Companies
Systematic Financial Management
Geode Capital Management
Millennium Management
Robeco Investment Management
Franklin Resources
Marshall Wace
Qube Research & Technologies

View all funds holding Innoviva